STOK STOKE THERAPEUTICS INC Management Changes 8-K Filing 2025 - Management Changes On March 18, 2025, Stoke Therapeutics announced its financial results for 2024 and reported that CEO Dr. Edward Kaye will step down on March 19, 2025, with Ian F. Smith appointed as Interim CEO. Dr. Kaye will receive a salary of $680,214 for 12 months post-transition and continue as an advisor.Get access to all SEC 8-K filings of the STOKE THERAPEUTICS INC